An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel disease
Virginia Solitano(Western University), Vipul Jairath(Western University), Britta Siegmund(Humboldt-Universität zu Berlin), Raja Atreya(Friedrich-Alexander-Universität Erlangen-Nürnberg), Bram Verstockt(Universitair Ziekenhuis Leuven), Julián Panés(Hospital Clínic de Barcelona), Remo Panaccione, Christopher Ma(University of Calgary), Saurabh Mehandru(Icahn School of Medicine at Mount Sinai), Robert Battat(Centre Hospitalier de l’Université de Montréal), Geert D’Haens(Amsterdam University Medical Centers), Tim Raine(National Health Service), Joana Torres(University of Lisbon), Jurij Hanžel(University of Ljubljana), Malcolm Hogan, Silvio Danese, Claire E Parker(Robarts Clinical Trials), Laurent Peyrin-Biroulet(Inserm), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Brian G. Feagan, Federica Ungaro(IRCCS Ospedale San Raffaele)
Cited by 9
Related Papers
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Immunology of COVID-19: Current State of the Science
|Immunity|2020|1.8k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
|Journal of Crohn s and Colitis|2019|1.1k